P16 (gene)

From Wikipedia, the free encyclopedia

Jump to: navigation, search


Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), also known as CDKN2A, is a human gene.

Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
PDB rendering based on 1a5e.
Available structures: 1a5e, 1bi7, 1dc2, 2a5e
Identifiers
Symbol(s) CDKN2A; ARF; CDK4I; CDKN2; CMM2; INK4; INK4a; MLM; MTS1; TP16; p14; p14ARF; p16; p16INK4; p16INK4a; p19
External IDs OMIM: 600160 Homologene55430
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 1029 na
Ensembl ENSG00000147889 na
Uniprot P42771 na
Refseq NM_000077 (mRNA)
NP_000068 (protein)
na (mRNA)
na (protein)
Location Chr 9: 21.96 - 21.98 Mb na
Pubmed search [1] na

This gene generates several transcript variants which differ in their first exons. At least three alternatively-spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM2, a protein responsible for the degradation of p53 [1]. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.[2]


p16 is a tumour suppressor gene. Mutations in p16 increase the risk of developing a variety of cancers, notably melanoma. p16 is an important gene in regulating the cell cycle.

Recent research on the p16 gene, published in Nature in September 2006, indicates that its increased expression as organisms age reduces the proliferation of stem cells. This reduction in the division and production of stem cells protects against cancer while increasing the risks associated with cellular senescence.

The p16 gene has an alternative reading frame (ARF) that encodes the p14 ARF protein. this is involved in stabilising P53 and is positively regulated by E2F.

p16INK4a is a major product of the CDKN2A locus. Its alternate reading frame product is p14ARF. p16INK4a regulates the cell cycle by binding and deactivating various cyclin-CDKcomplexes. A study published in 2007 in the New England Journal of medicine established that there is a strong association between polymorphisms on chromosome 9p21.3 (SNP, rs1333049) and coronary artery disease. This region codes for the INK4 proteins p16INK4a and p15INK4b. The corresponding genes are CDKN2A and CDKN2B. The proteins may inhibit cell growth induced by Transforming Growth Factor-beta.


  1. ^ "Molecular biology of cancer", Oxford University Press, 2005, ISBN 978-0-19-926472-8, Section 5.3
  2. ^ Entrez Gene: CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4).

Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.